BR112014005080A2 - métodos para o tratamento de câncer de mama - Google Patents

métodos para o tratamento de câncer de mama

Info

Publication number
BR112014005080A2
BR112014005080A2 BR112014005080A BR112014005080A BR112014005080A2 BR 112014005080 A2 BR112014005080 A2 BR 112014005080A2 BR 112014005080 A BR112014005080 A BR 112014005080A BR 112014005080 A BR112014005080 A BR 112014005080A BR 112014005080 A2 BR112014005080 A2 BR 112014005080A2
Authority
BR
Brazil
Prior art keywords
methods
breast cancer
treating breast
treating
cancer
Prior art date
Application number
BR112014005080A
Other languages
English (en)
Inventor
Ordentlich Peter
Goodenow Robert
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47756940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014005080(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of BR112014005080A2 publication Critical patent/BR112014005080A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BR112014005080A 2011-09-02 2012-08-31 métodos para o tratamento de câncer de mama BR112014005080A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530873P 2011-09-02 2011-09-02
US201161532534P 2011-09-08 2011-09-08
US201161628999P 2011-11-12 2011-11-12
US201161568110P 2011-12-07 2011-12-07
PCT/US2012/053551 WO2013033656A1 (en) 2011-09-02 2012-08-31 Methods for the treatment of breast cancer

Publications (1)

Publication Number Publication Date
BR112014005080A2 true BR112014005080A2 (pt) 2017-03-28

Family

ID=47756940

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005080A BR112014005080A2 (pt) 2011-09-02 2012-08-31 métodos para o tratamento de câncer de mama

Country Status (15)

Country Link
US (2) US10226472B2 (pt)
EP (2) EP2751267B1 (pt)
JP (2) JP6195384B2 (pt)
KR (1) KR101956861B1 (pt)
CN (3) CN114053284A (pt)
AU (2) AU2012301616B2 (pt)
BR (1) BR112014005080A2 (pt)
CA (1) CA2847348A1 (pt)
EA (1) EA201201474A1 (pt)
ES (1) ES2663407T3 (pt)
GE (1) GEP201706612B (pt)
HK (1) HK1254859A1 (pt)
MX (1) MX358254B (pt)
UA (6) UA124241U (pt)
WO (1) WO2013033656A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2847348A1 (en) 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Acetylation detection in the treatment of breast cancer with entinostat and an aromatase inhibitor
JP2016522188A (ja) * 2013-05-03 2016-07-28 シンダックス ファーマシューティカルズ，インク． 癌の処置方法
US20180104232A1 (en) * 2015-03-12 2018-04-19 The University Of Chicago Methods for determining prognosis for breast cancer patients
AU2016318136B2 (en) * 2015-09-02 2022-10-20 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
US20190282541A1 (en) * 2016-07-20 2019-09-19 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
US12000829B2 (en) 2018-05-07 2024-06-04 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
KR102212699B1 (ko) 2019-08-12 2021-02-05 한국원자력의학원 유방암 예방 또는 치료용 조성물
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US12017506B2 (en) 2020-08-20 2024-06-25 Denso International America, Inc. Passenger cabin air control systems and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
WO2008021542A2 (en) * 2006-08-17 2008-02-21 Cell Signaling Technology, Inc. Lysine acteylation sites
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US8110550B2 (en) 2007-06-06 2012-02-07 University Of Maryland, Baltimore HDAC inhibitors and hormone targeted drugs for the treatment of cancer
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
RU2013140471A (ru) 2011-02-02 2015-03-10 Дженентек, Инк. Дозирование для лечения антителами против egfl7
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CA2847348A1 (en) 2011-09-02 2013-03-07 Syndax Pharmaceuticals, Inc. Acetylation detection in the treatment of breast cancer with entinostat and an aromatase inhibitor
CH706458B1 (fr) 2012-04-30 2017-05-15 Granit Tech Sa Procédé de cimentation pour le stockage de déchets.

Also Published As

Publication number Publication date
US20190343844A1 (en) 2019-11-14
UA124239U (uk) 2018-03-26
CN103906837A (zh) 2014-07-02
EP2751267A1 (en) 2014-07-09
MX358254B (es) 2018-08-10
ES2663407T3 (es) 2018-04-12
UA123212U (uk) 2018-02-26
CA2847348A1 (en) 2013-03-07
UA124238U (uk) 2018-03-26
KR101956861B1 (ko) 2019-03-12
AU2012301616A1 (en) 2014-04-17
EP2751267B1 (en) 2018-01-24
JP6195384B2 (ja) 2017-09-13
HK1254859A1 (zh) 2019-07-26
US10226472B2 (en) 2019-03-12
EP3381454A1 (en) 2018-10-03
EP2751267A4 (en) 2015-01-07
EA201201474A1 (ru) 2013-08-30
WO2013033656A1 (en) 2013-03-07
UA149007U (uk) 2021-10-13
UA124240U (uk) 2018-03-26
UA124241U (uk) 2018-03-26
MX2014002515A (es) 2015-05-07
AU2018203059A1 (en) 2018-05-17
US20140378420A1 (en) 2014-12-25
AU2012301616B2 (en) 2018-02-08
KR20140108629A (ko) 2014-09-12
GEP201706612B (en) 2017-02-10
JP2017149761A (ja) 2017-08-31
CN114053284A (zh) 2022-02-18
CN107982270A (zh) 2018-05-04
JP2014525465A (ja) 2014-09-29

Similar Documents

Publication Publication Date Title
IL273517A (en) Cancer treatment methods
BR112014005080A2 (pt) métodos para o tratamento de câncer de mama
BR112014032105A2 (pt) método para o tratamento de câncer
BR112014002200A2 (pt) tratamento de câncer de mama
BR112014007603A2 (pt) métodos de tratamento do câncer
IL237558A0 (en) Methods for treating locally advanced breast cancer
HK1220155A1 (zh) 治療癌症的方法
BR112014031806A2 (pt) método para tratamento de câncer positivo para gd2
BR112014028424A2 (pt) compostos de pirimidina para o tratamento de câncer
ZA201205003B (en) Methods for treating breast cancer
HK1202240A1 (en) Methods of treating cancer
EP2698634A4 (en) BIOMARKER FOR BREAST CANCER
IL228644A0 (en) Cancer treatment methods
IL254964A0 (en) A method for treating breast cancer
EP2894477A4 (en) METHOD FOR DETECTION OF BREAST CANCER
ZA201503005B (en) Ingenol-derived compounds useful for treating cancer
PL3016682T3 (pl) Sposoby leczenia nowotworu
EP2886122A4 (en) AGENT FOR THE TREATMENT OF CANCER
BR112014028306A2 (pt) métodos para tratamento de câncer gástrico.
EP2888594A4 (en) METHOD OF DETERMINING TREATMENT FOR USE AGAINST BREAST CANCER
BR112013004389A2 (pt) método imunoterapêutico para tratamento do câncer de próstata
ZA201504169B (en) Anti-adam28 antibody for treating cancer
ZA201501123B (en) Improved methods for treating cancer with reduced renal toxicity
IL238267A0 (en) Anthracycline derivatives for the treatment of tumor diseases
BR112015008366A2 (pt) método de tratamento de câncer

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 15/09

Ipc: A61K 31/4406 (2000.01), A61P 35/00 (2000.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]